DTA | pharmaphorum

Skip to main content

Tuesday 5 November 2024

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

DTA

Digital

pharmaphorum podcast episode 105a

Why digital therapeutics (DTx) are effective and safe, but n...

In a new episode of the pharmaphorum podcast, host Nicole Raleigh welcomes Joel Morse, CEO and co-founder of Curavit Clinical Research, and Andy Molnar, CEO of the Digital Therapeutics Alli

Views & Analysis

MeganFH22_2

Frontiers Health Steering Committee spotlight: Megan Coder

As Frontiers Health approaches, we’re featuring interviews with members of the steering committee to give you a sneak peek of what to expect in Milan. Interested in signing up?

Digital

digital therapeutics health evaluation DTA

Defining the digital therapeutics opportunity

Once the stuff of science fiction, an emerging category of medicine is set to be increasingly influential in healthcare.

Digital

Digital therapeutics definition dta

Expanding the definition of medicine

Digital therapeutics are adding new elements to the medical world, but their place in the pharmaceutical sector is not yet fully established.

Editor's Picks

Novo Nordisk will file semaglutide for MASH next year

Eledon drug helps transplants 'cure' type 1 diabetes

UK Chancellor pledges £22bn rise in day-to-day NHS spending

Teva fined €462.6m for antitrust delay to MS drug rivals

Novartis pays $150m upfront for Monte Rosa degrader drug

News

Lab space in CRUK's Paterson Building in Manchester

CRUK backs AI-powered, virtual radiotherapy trial projects

Cancer Research UK has provided £5.9 million ($7.7 million) in funding to a project that will explore the use of artificial intelligence in trials of radiotherapy treatments as well as virt

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Needle with colourful threads

Sponsored

Global reach, personal touch: Mastering customer engagement ...

In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company